PhageTech, Inc.

www.phagetech.com

PhageTech, Inc. is a California-based, developmental stage company applying an innovative approach for detecting disease markers in body fluids including urine and blood. Compared to current antibody-based assays, PhageTech's approach could offer improved sensitivity and performance. Furthermore, our technology has the potential to be more stable and less expensive than current testing methods. The PhageTech, Inc. technology platform promises to deliver rapid and accurate diagnostic screening for testing at a fraction of current costs. The core technology utilized in PhageTech devices was developed by two research groups at the University of California, Irvine, and was the subject of nine pending and issued patents. Recently, protein sensing with the PhageTech platform has been demonstrated with PSMA (Prostate-specific membrane antigen) and HSA (Human Serum Albumin). These targets could impact the diagnosis of prostate cancer and kidney disease, respectively. Our technology has the potential to touch every field of medicine and profoundly impact the administration of health care around the world.

Read more

Reach decision makers at PhageTech, Inc.

Lusha Magic

Free credit every month!

PhageTech, Inc. is a California-based, developmental stage company applying an innovative approach for detecting disease markers in body fluids including urine and blood. Compared to current antibody-based assays, PhageTech's approach could offer improved sensitivity and performance. Furthermore, our technology has the potential to be more stable and less expensive than current testing methods. The PhageTech, Inc. technology platform promises to deliver rapid and accurate diagnostic screening for testing at a fraction of current costs. The core technology utilized in PhageTech devices was developed by two research groups at the University of California, Irvine, and was the subject of nine pending and issued patents. Recently, protein sensing with the PhageTech platform has been demonstrated with PSMA (Prostate-specific membrane antigen) and HSA (Human Serum Albumin). These targets could impact the diagnosis of prostate cancer and kidney disease, respectively. Our technology has the potential to touch every field of medicine and profoundly impact the administration of health care around the world.

Read more
icon

Country

icon

State

California

icon

City (Headquarters)

Glendale

icon

Employees

11-50

icon

Founded

2014

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Chairman of the Board

    Email ****** @****.com
    Phone (***) ****-****
  • Co - Founder , Advisor

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Executive Officer

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(9)

Reach decision makers at PhageTech, Inc.

Free credits every month!

My account

Sign up now to uncover all the contact details